The latest and largest Risperdal jury award is the fifth instance where juries found that the makers of Risperdal did not provide adequate warning of Risperdal’s risks to patients and doctors.
A Philadelphia jury awarded Andrew Yount $70 million after he suffered from Risperdal side effects. The Tennessee boy started taking Risperdal in 2003 when he was just five years old and developed gynecomastia (male breast growth) just one year after taking the anti-psychotic medication.
During the trial, it was the boy’s father testimony that convinced the jury that the giant drug company intentionally falsified, concealed or destroyed evidence. Attorneys’ representing Yount argued that Janssen, the manufacturer of Risperdal, knew about the link between Risperdal and gynecomastia yet decided to withhold that information. Yount’s attorneys provided Janssen’s internal documents that showed it purposely limited the medical community’s understanding of the risks associated with Risperdal.